The U.S. Court of Appeals for the Federal Circuit denied West-Ward Pharmaceutical Corp.'s petitions challenging the outcome of a patent infringement suit.

The subsidiary of London-based Hikma Pharmaceuticals PLC was seeking a rehearing on the court's earlier decision to uphold the U.S. District Court for the District of Delaware's ruling that said it had infringed on U.S. patent number 8,586,610 covering Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt.

Washington, D.C.-based Vanda said the patent will expire Nov. 2, 2027.